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Abstract 
 
Objective: The objective of this selective EBM review is to determine whether or not 
curcuminoids are effective in improving physical function in patients with knee osteoarthritis. 
 
Study Design: Review of a double-blind randomized control trial, a randomized control trial, and 
a randomized single-blind placebo-controlled trial.  
 
Data Sources: The articles were found on PubMed and selected based on the relevance to the 
clinical question and if they were focused on patient-oriented evidence that matters (POEM).  
 
Outcomes Measured: The outcomes were based solely on function measures using a patient rated 
WOMAC scale (WOMAC function) (patient satisfaction of treatment on a 5-category scale 
(high, moderate, little, same, or dissatisfaction), an investigator based Clinician Global 
Impression of Change (CGIC), a 6-minute walk distance), and time spent during a 100-meter 
walk and going up and down a flight of stairs. This study focuses on the WOMAC scale and time 
spent during a 100-meter walk. 
 
Results: Kuptniratsaikul, et. al (2014) found that C. domestica extracts were just as effective as 
Ibuprofen in treating knee OA and had a similar side effect profile, with less GI side effects than 
ibuprofen. Kuptniratsaikul, et. al (2009) also found that C. domestica extracts seemed just as 
effective and safe at treating knee OA as ibuprofen, but was not statistically different enough to 
be definitive. Madhu, et. al found NR-INF-02 to be an acceptable and tolerable option in the 
treatment of knee OA.  
 
Conclusions: Based on these three randomized, controlled clinical trials, the efficacy of 
curcuminoids on knee osteoarthritis is likely to be an effective alternative treatment method to 
improve functionality. The populations studied in these trials were not large and should be 
considered and addressed in future studies.   
 
Key Words: Turmeric, arthritis, randomized controlled trial  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Miranda, Curcuminoids and Knee OA 1 
Introduction 
 Worldwide, knee osteoarthritis (OA) is a major public health concern, being the most 
common degenerative joint disorder in the elderly.1 In osteoarthritis, cartilage between the bones 
begins to break down leading to pain, swelling, and difficulty moving the effected joint.2 Over 
time, OA worsens causing bony spur formation, pieces of broken off bone or cartilage to float in 
the joint space, and inflammation.2 This inflammation further damages the cartilage.2 In the final 
stages of OA, the cartilage has been completely worn out which causes bone to rub against bone 
resulting in increased pain, inflammation, and damage, and decreased joint function.2   
The symptoms of knee OA are secondary to the degradation of collagen and include a 
gradual onset of pain and stiffness in the joint, most likely occurring first thing in the morning or 
soon after resting.2 Symptoms also include swelling that gets worse with extended activity, 
limited ROM that increases after movement, pain that can worsen at the end of the day, and 
crepitation that occurs when joint is bent.2 There are many different causes and risk factors of 
OA. The first is an increased weight/BMI that can cause cartilage cushions to break down faster.2 
Injury or overuse of a joint can also cause OA.2 Although the exact genetic cause is unknown, 
scientists believe that there is a rare defect in the production of collagen or a defect in the way 
bones fit together.2 
 Knee OA is a common joint disorder affecting many people and incurring increasingly 
high healthcare costs every year. It affects approximately 30.8 million Americans.3 It is also 
estimated that 1 in 2 people in the US, at some point in their lives, will develop knee OA 
symptoms.4 Most patients spend approximately 13 years with symptomatic knee OA before 
receiving a total knee arthroplasty (TKA), instead supplementing with pharmacologics.4 These 
patients had an average of 6 more yearly MD visits and 3.8 more non-MD visits than patients 
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without knee OA.5  Eventually, most patients with knee OA will need to receive a TKA, with an 
average of 658,000 Americans receiving one every year resulting in a 28% increase in hospital 
stays.4,5 As a result of increased visits, pharmacologic supplementation, TKAs, and associated 
hospital stays, it is estimated that knee OA contributes in excess of 27 billion dollars in 
healthcare costs every year.4 In 2011 alone, Medicare reimbursed healthcare systems 3.5 billion 
dollars for TKAs, which is a higher cost than heart failure, spinal fusions, or coronary stents.4 
 There are various treatment methods that can be used to increase functionality in patients 
with knee osteoarthritis. Non-pharmacologic methods include weight management, stretching, 
PT/OT, and assistive devices.2 Furthermore, you can do various physical activities, including 
strengthening, ROM exercises, and aerobic exercises.2 Pharmacologic treatments can include 
pain and anti-inflammatory medications like analgesics, NSAIDs, corticosteroids, or hyaluronic 
acid.2 It can also include natural and alternative methods like supplements, acupuncture, 
acupressure, and massage.2 Most patients will need a TKA at some point in their struggle with 
knee OA.2  
 Although there are many different treatment options available to treat the decreased 
functionality that comes with knee OA, some of the treatment options have increased side effect 
profiles. Also, some patients are not able to implement available treatment modalities due to 
other comorbid conditions and the effects certain medications might have on them. 60-90% of 
patients with knee OA are interested in alternative methods of medicine, and curcuminoids fall 
into that category in the treatment of knee OA.4 Curcuminoids inhibit the effect of substances 
found in the inhibitory pathway (lipoxygenase, cyclooxygenase, phospholipase, etc.) and pro-
inflammatory cytokines (IL-1 beta, IL-8, TNF-alpha, etc.).1  
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Objective 
 The objective of this selective EBM review is to determine whether curcuminoids are 
effective in improving physical function in patients with knee osteoarthritis. 
Methods 
 Criteria used for selection of studies for this systematic review is based on specific 
populations, interventions, comparisons, outcomes measured, and the type of study that was 
done. The population studied was any patient, male or female, greater than 40 years of age with 
knee osteoarthritis. None of the patients had an allergy to curcuminoids or co-existing conditions 
that could impede the success of the trial. The interventions studied were the use of curcuminoids 
versus a placebo, ibuprofen, or glucosamine sulfate when comparing the effective treatment of 
knee OA. The outcome measured was the improvement of physical function with the use of 
curcuminoids using methods that centered around patient-oriented evidence that matters 
(POEM). The studies used in this systematic review include a double-blind randomized control 
trial, a randomized control trial, and a randomized single-bind placebo-controlled trial. 
 Research for this systematic review was found using PubMed. The studies were 
randomized controlled trials and the articles were published in peer-reviewed journals within the 
last 10 years. All articles were written in the English language. The keywords used when 
searching for these articles were “turmeric”, “arthritis”, and “randomized controlled trial”. The 
articles were selected for this systematic review based on the relevance to the objective. This 
includes patients that were greater than 40 years old who had been diagnosed knee OA and 
whether or not the articles’ outcomes were based on patient-oriented evidence that matters. The 
exclusion criteria excluded papers that included patients less than 40 years old, studies that were 
not randomized or controlled, and studies that had outcomes that were not based on patient-
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oriented evidence that matters. The statistics used or reported in these studies were change in the 
mean baseline. The data from the articles was analyzed using p-values and Confidence Intervals 
using continuous data to analyze the efficacy of curcuminoids in improving physical function in 
patients with knee osteoarthritis compared to placebos or alternative treatment methods.  
Outcomes Measured 
 The outcome that was measured in these studies was a change in physical function in 
patients with knee osteoarthritis. Kuptniratsaikul et. al (2014) assessed physical function in the 
patients using a modified Thai version of the Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC) scale, with a focus on the WOMAC function subscale.1 The 
scale has a range from 0 to 10, with a higher score representing worse knee function.1 They also 
used a 6-minute walk distance to evaluate function.1 These assessments were completed at weeks 
2 and 4 during treatment follow-up.1 At the end of the trial, patients were asked to complete a 
global assessment and satisfaction survey.1 The patients were also asked to report any adverse 
events that occurred throughout the study, recorded as any new symptoms the patients 
experienced.1 
  Kuptniratsaikul, et. al (2009) assessed physical function in the patients based on time 
spent on a 100-meter walk and time spent going up and down a flight of stairs (10 steps).6 For 
both exercises, the time was measured using a digital stopwatch that had a resolution within 
0.001 seconds.6 Each participant was analyzed by the same assessor at every visit, and all 
patients completed the exercises at the same location.6 The patients were assessed at weeks 2, 4, 
and 6.6 Throughout the study, patients reported any adverse events as either new symptoms 
experienced or a change in lab profiles completed at week 0 and week 6 that included a complete 
blood count, liver function, and renal function.6 At the end of the trial during the 6 week follow-
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up, patients were asked to complete a patient satisfaction survey evaluated by a 5-category scale: 
high, moderate, little, same, or dissatisfaction.6 
 Madhu, et. al assessed physical function in the patients based on the Likert Version-3.0 of 
the WOMAC, which was modified for Indian use.4 The WOMAC scale had 24 questions, with 
questions 8-24 focusing on physical functional difficulty.4 The responses were quantitative: 0 
being none, 1 being mild, 2 being moderate, 3 being severe, and 4 being extreme.4 The highest 
score possible was a 96.4 This was completed on days 0, 21, and 42.4 The Clinician Global 
Impression of Change (CGIC) was assessed by clinical examination by a designated orthopedic 
consultant and had an emphasis on the presence or absence of the limitation of movement, 
crepitus, muscle wasting, and subluxation of joint.4 This was completed on days 21 and 42 of 
trial follow-up.4 At the end of the trial, the acceptability of medications by study patients 
wherever available was evaluated as 0-3: 0 being not acceptable, 1 being good, 2 being better, 
and 3 being best.4 Patients were also asked to report any adverse events throughout the trial.4 
Three articles were chosen for this systematic review. Table 1 represents the demographics and 
characteristics of each study that was selected.  
Results 
 Three randomized, controlled trials were chosen for this systematic review to determine 
the efficacy and safety of curcuminoids for the improvement of function in patients with knee 
osteoarthritis. The Kuptniratsaikul, et. al (2014) study used continuous data that was not 
convertible into dichotomous form.1 The data was analyzed using a per-protocol analysis.1 The 
Kuptniratsaikul, et. al (2009) study also used continuous data that was not convertible into 
dichotomous data.6 Like the previous study, the data was not based on an intention-to-treat-
analysis, but instead it was based on a per-protocol analysis.6 The Madhu, et. al study also used 
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Table 1: Demographics & Characteristics of included studies  
Study Type # 
Pts 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Kuptnir-
atsikul, 
2014 
RCT 367 ≥ 50 Pts who had 
primary knee 
OA with a 
numerical pain 
scale >5/10 and 
≥50 y.o. 
Pts who had 
abnormal liver or 
kidney function, 
history of peptic 
ulcer, allergy to 
curcumin or 
ibuprofen, or 
unable to walk 
36 C. domestica 
extracts 1,500 
mg/day VS. 
Ibuprofen 
1,200 mg/day 
Kuptnir-
atsikul, 
2009 
RCT 107 > 50 Pts who had 
primary knee 
OA, knee pain, 
radiographic 
osteophytes and 
1 of the 
following: 1) age 
> 50 years, 2) 
morning stiffness 
30 mins in 
duration, 3) and 
crepitus on 
motion 
Pts who had 
peptic ulcers, 
hepatobiliary 
tract disease, or 
known allergy to 
curcumin or 
ibuprofen 
16 C. domestica 
extracts 2 
g/day VS. 
Ibuprofen 800 
mg/day 
Madhu, 
2013 
RCT 120 > 40 Pts who were 
either gender, > 
40 y.o., clinical 
evidence 
confirming 
diagnosis of 
knee OA, 
duration of pain 
at least 6 months 
on majority of 
days during 
preceding 
months, and 
showing 
radiological 
evidence of knee 
OA Grade 2 or 
Grade 3 
Pts who had 
medical or 
arthritic 
conditions 
confounding 
evaluation of 
knee OA, 
Primary 
predominant 
patella-femoral 
disease, history 
of clinically 
significant 
trauma/surgery 
to affected knee, 
and co-existing 
disease that 
could preclude 
the successful 
completion of 
the trial 
10 NF-INF-02 
500 mg BID 
VS. 
Glucosamine 
Sulfate (GS) 
750 mg BID 
VS.   
Combo of 
NF-INF-02 
and GS 
VS. Placebo 
400 mg BID 
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continuous data that was not convertible into dichotomous data; however, it was based on an 
intention-to-treat analysis.4 All three studies analyzed the measured outcomes based on change in 
mean baseline of improvement of physical function of the patients.  
 In the Kuptniratsaikul, et. al (2014) study, 367 patients were initially included in the 
study based on inclusion and exclusion criteria. 331 patients were able to finish the study with 36 
lost to follow-up (Table 1). This meant that 171 patients were left in the C. domestica extracts 
group and 160 were left in the ibuprofen group.1 The patients either received 1,500 mg/day of C. 
domestica or 1,200 mg/day of ibuprofen, with both treatment options being made to look 
identical.1 Patients were asked to take 2 capsules after meals three times a day for 4 weeks and to 
not use any other medications during the study, except recorded Tramadol as a rescue medication 
for severe pain.1 The outcomes were evaluated at weeks 2 and 4 by the same assessor at each 
site.1 At week 4, the WOMAC function scale showed a non-inferiority of C. domestica extract as 
a treatment when compared to ibuprofen (p-value = 0.010) (Table 2).1 The baseline WOMAC 
function score was not significantly different between the two groups at the beginning of the 
study (Table 2).1 One hundred and twenty patients (29.7% in the C. domestica group and 35.7% 
in the ibuprofen group) reported adverse events including dyspepsia, abdominal pain, nausea, 
loose stools, and pitting edema.1 C. domestica had lower GI side effects overall than ibuprofen.1 
 
Table 2: Mean WOMAC Function Score at the Beginning and End of Treatment1 
 C. domestica extracts 
(n=171) 
Ibuprofen 
(n=160) 
P-value 
WOMAC functions (beginning) 5.3±2.0 5.1±1.8 0.440 
WOMAC function  
(end, adjusted by week 0) 
3.41±2.09 3.26±2.05 0.010 
  
 When looking at the WOMAC function score, the change from week 0 to week 4 was an 
improvement of 3.41±2.09. This is a large improvement since the scale was based on a 0-10 
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measure, despite the standard deviation being wide. The confidence interval was at 95% and the 
p-value was ≤ 0.05 at 0.01. Keeping these statistics in mind, it can be confidently said that C. 
domestica is a statistically significant treatment and would be a non-inferior treatment in a large 
population.  
 In the Kuptniratsaikul, et. al (2009) study, 107 patients were initially included in the 
study based on inclusion and exclusion criteria. 91 patients were able to finish the study with 16 
lost to follow-up (Table 1). This meant that 45 patients were left in the C. domestica extracts 
group and 46 were left in the ibuprofen group.6 The patients either received 500 mg four times a 
day of C. domestica extracts or 400 mg twice a day of ibuprofen, with instructions not to use any 
other medicines or herbs.6 The outcomes were evaluated at weeks 0, 2, 4, and 6 by the same 
assessor at each site.6 At week 6, the time spent on a 100-meter walk suggests that C. domestica 
extracts might be as effective as ibuprofen in improving function, but the values were not 
statistically different (p-value = 0.16) (Table 3).6 Thirty-nine patients (16 in the C. domestica 
group and 23 in the ibuprofen group) reported adverse events including dyspepsia, dizziness, 
nausea and vomiting, and loose stools.6 C. domestica had lower GI side effects overall than 
ibuprofen.6 
Table 3: Change in Time Spent Walking 100-meters Between the Beginning and End of 
Treatment6 
 C. domestica extracts 
(n=45) 
Ibuprofen 
(n=46) 
Difference of Change Score 
(95% CI) 
P-value 
Change Score 
(sec) 
10.1±16.8 5.0±16.9 5.07 
(-2.09 to 12.23) 
0.16 
 
When looking at the time spent walking 100-meters, the difference in mean change 
scores from week 0 to week 6 was a difference of 5.07 seconds with a 95% confidence interval 
between -2.09 and 12.23. This is a small improvement since the C. domestica group only 
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improved 5 seconds more than the ibuprofen group and the confidence interval is wide. If the 
confidence interval was narrowed and the difference in change score had increased, it would be a 
large improvement. The confidence interval was at 95% and the p-value was > 0.05 at 0.16. 
When interpreting the statistics, it can be confidently said that the treatment was not statistically 
significant and may not be a good treatment option in a large population. 
In the Madhu, et. al study, 120 patients were initially included in the study based on 
inclusion and exclusion criteria. 110 patients were able to finish the study with 10 lost to follow-
up (Table 1). This meant that 29 patients were left in the NR-INF-02 group, 28 in the 
glucosamine sulfate (GS) group, 24 in the NR-INF-02 + GS group, and 29 in the placebo group.4 
The NR-INF-02 group received one 500 mg capsule twice a day, the GS group received two 375 
mg capsules twice a day, the NR-INF-02 + GS received one 500 mg capsule twice a day and two 
375 mg capsules twice a day (respectively), and the placebo group received one 400 mg capsule 
twice a day.4 The outcomes were evaluated at days 0, 21, and 42.4 Acetaminophen tablets 2,000-
4,000 mg per day were allowed as a rescue medication, except 24 hours before clinical 
examination of the knee joint.4 At day 42, the WOMAC score showed a significantly higher 
reduction in the NR-INF-02 groups when compared to the placebo and NS-INR02 + GS group 
(p-value < 0.05); however, there were so significant difference when compared to the GS group 
(Table 4).4 The baseline WOMAC function score was not significantly different between the four 
groups at the beginning of the study (Table 4).4 Thirteen patients (2 in the NR-INF-02 group, 5 
in the GS group, 4 in the NR-INF-02 + GS group, and 2 in the placebo group) reported adverse 
events including dyspepsia, fever, sore throat, pedal edema, generalized body pain, and cough.4 
NR-INF-02 had the least number of adverse events during the trial.4 
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Table 4: Effect of Treatment on WOMAC over 21st Day and 42nd Day Follow-Up 
 NR-INF-02 
(n=29) 
Glucosamine 
(n=24) 
NR-INF-02 +GS 
(n=24) 
Placebo 
(n=29) 
Baseline 54.97±9.85 58.30±12.73 60.73±11.47 57.23±9.63 
21st Day1 36.67±16.08a,b 44.17±15.77 47.31±19.16 52.23±9.63 
42nd Day2 27.14±16.13a, b 34.92±19.48 36.21±24.74 47.90±12.59 
1  Significantly different from baseline to first follow-up (p < 0.01); 2  Significantly different from 
baseline to second follow-up (p < 0.01); a  Significantly different from Placebo (p <0.05); b  Significantly 
different from NR-INF-02 + GS (p<0.05) 
 
 When looking at the WOMAC score, the score was significantly different on day 42 than 
when compared to the baseline (p-value < 0.01). The confidence interval was not given, but the 
p-value was < 0.01 and was significantly different than the NR-INF-02 + GS and placebo groups 
with a p-value of < 0.05. Keeping these statistics in mind, it can be confidently said that NF-
INR-02 is a statistically significant treatment and would be an acceptable and tolerable treatment 
option in a large population. 
Discussion 
 This systematic review compares three randomized, controlled clinical trials, and two out 
of three of them found that curcuminoids are statistically effective at improving physical 
function in people with knee osteoarthritis.1, 4, 6 Kuptniratsaikul, et. al (2014) found significant 
improvement in the WOMAC function subscale.1 Kuptniratsaikul, et. al (2009) did not find 
significant improvement in the time it took to walk 100-meters.6 Madhu, et. al found significant 
improvement in the WOMAC score.4  
 For a long time, curcumin has been used as a spice and coloring agent in Thai curry 
powders.1 In Ayurvedic and Chinese medicine, it has been used as an anti-oxidant, for its anti-
inflammatory properties, to aid in digestion, to treat liver problems and skin disease, and to aid in 
wound healing.7 In food, curcumin is considered safe; however, large amounts for long periods 
of time can cause stomach upset and ulcers.7 It can also lower blood sugars, so should be used 
with caution in diabetics.7 Furthermore, it can cause blood thinning, so it should be discontinued 
 Miranda, Curcuminoids and Knee OA 11 
at least two weeks before a planned surgery.7 It should be used with caution if one is taking: 
blood thinners, diabetic medicines, proton pump inhibitors, or antacids/antihistamines.7 
 Kuptniratsaikul, et. al (2014) mentioned that they were concerned about the dosage of 
ibuprofen used in the active control group.1 They chose a 1,200-mg dosage instead of a higher 
dosage of 1,800 mg at the recommendation of a rheumatologist due to the smaller body habitus 
of the Thai population.1 Kuptniratsaikul, et. al (2009) mentioned that the wide range of 95% CI 
indicated that their study had an inadequate sample size.6 They also had concerns about the 
amount of C. domestica dosages needed throughout the day and the low dosage of ibuprofen 
used, which was 400 mg twice daily.6 They suggested another study with a bigger sample size 
and increased dosage of ibuprofen.6 Madhu, et. al considered a few limitations in their study 
including: 1) small sample size; 2) study being single blind; 3) short duration of treatment; and 4) 
subjective scales.4 They suggested that future studies should include a large sample group and a 
longer duration of treatment.4 
Conclusion 
 Based on these three randomized, controlled trials, the efficacy of curcuminoids is 
inconclusive, with only two out of the three studies finding statistically significant improvement 
in physical function when using curcuminoids as treatment.1, 4, 6 In future studies, it would be 
appropriate to have larger sample sizes and longer duration of studies. If researchers focused on 
these two areas, they would give a more accurate portrayal of and validate the efficacy of 
curcuminoids in improving physical function in the general population of patients with knee 
osteoarthritis. 
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